Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Indapamide in SPMS
NCT05013463Phase 2Unknown
- Sponsor
- University of Calgary
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine, indapamide in secondary-progressive multiple sclerosis (SPMS), sponsored by University of Calgary. Status: unknown.
02
Drugs
hydroxychloroquineindapamide
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT05013463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013463.